Cargando…

Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model

BACKGROUND: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Eun Jung, Ahn, Junhyun, Gwak, Sang Won, Park, Kyung Su, Baik, Seung Hyuk, Hwang, Sung-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132421/
https://www.ncbi.nlm.nih.gov/pubmed/30027459
http://dx.doi.org/10.1245/s10434-018-6628-x
_version_ 1783354318085160960
author Park, Eun Jung
Ahn, Junhyun
Gwak, Sang Won
Park, Kyung Su
Baik, Seung Hyuk
Hwang, Sung-Joo
author_facet Park, Eun Jung
Ahn, Junhyun
Gwak, Sang Won
Park, Kyung Su
Baik, Seung Hyuk
Hwang, Sung-Joo
author_sort Park, Eun Jung
collection PubMed
description BACKGROUND: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. METHODS: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal(®) PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision(®)). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m(2)) or oxaliplatin (460 mg/m(2)). The plasma area under the curve (AUC; AUC(plasma)), peritoneal AUC (AUC(peritoneum)), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. RESULTS: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal(®) (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC(peritoneum) did not vary (p = 0.941), the AUC(plasma) of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). CONCLUSIONS: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-018-6628-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6132421
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-61324212018-09-14 Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model Park, Eun Jung Ahn, Junhyun Gwak, Sang Won Park, Kyung Su Baik, Seung Hyuk Hwang, Sung-Joo Ann Surg Oncol Colorectal Cancer BACKGROUND: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. METHODS: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal(®) PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision(®)). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m(2)) or oxaliplatin (460 mg/m(2)). The plasma area under the curve (AUC; AUC(plasma)), peritoneal AUC (AUC(peritoneum)), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. RESULTS: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal(®) (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC(peritoneum) did not vary (p = 0.941), the AUC(plasma) of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). CONCLUSIONS: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-018-6628-x) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-07-18 2018 /pmc/articles/PMC6132421/ /pubmed/30027459 http://dx.doi.org/10.1245/s10434-018-6628-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Colorectal Cancer
Park, Eun Jung
Ahn, Junhyun
Gwak, Sang Won
Park, Kyung Su
Baik, Seung Hyuk
Hwang, Sung-Joo
Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model
title Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model
title_full Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model
title_fullStr Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model
title_full_unstemmed Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model
title_short Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model
title_sort pharmacologic properties of the carrier solutions for hyperthermic intraperitoneal chemotherapy: comparative analyses between water and lipid carrier solutions in the rat model
topic Colorectal Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132421/
https://www.ncbi.nlm.nih.gov/pubmed/30027459
http://dx.doi.org/10.1245/s10434-018-6628-x
work_keys_str_mv AT parkeunjung pharmacologicpropertiesofthecarriersolutionsforhyperthermicintraperitonealchemotherapycomparativeanalysesbetweenwaterandlipidcarriersolutionsintheratmodel
AT ahnjunhyun pharmacologicpropertiesofthecarriersolutionsforhyperthermicintraperitonealchemotherapycomparativeanalysesbetweenwaterandlipidcarriersolutionsintheratmodel
AT gwaksangwon pharmacologicpropertiesofthecarriersolutionsforhyperthermicintraperitonealchemotherapycomparativeanalysesbetweenwaterandlipidcarriersolutionsintheratmodel
AT parkkyungsu pharmacologicpropertiesofthecarriersolutionsforhyperthermicintraperitonealchemotherapycomparativeanalysesbetweenwaterandlipidcarriersolutionsintheratmodel
AT baikseunghyuk pharmacologicpropertiesofthecarriersolutionsforhyperthermicintraperitonealchemotherapycomparativeanalysesbetweenwaterandlipidcarriersolutionsintheratmodel
AT hwangsungjoo pharmacologicpropertiesofthecarriersolutionsforhyperthermicintraperitonealchemotherapycomparativeanalysesbetweenwaterandlipidcarriersolutionsintheratmodel